U10. Drug Formulation
-
- Scientific Director: Prof. José Luis Pedraz joseluis.pedraz@ehu.es
- Scientific Coordinator: Dr. Idoia Gallego Garrido idoiagallego@hotmail.com
- Entities: Universidad del País Vasco (UPV/EHU)
- Address: Pharmacy & Pharmac. Technology Lab.; Facultad de Farmacia, C/Paseo de la Universidad 7, 01006 Vitoria-Gasteiz (Spain)
- Phone: +34 653593042
- Fax: +34 945 013040
- Web: NANOBIOCEL UPV/EHU
Order request
Description
Located at the Faculty of Pharmacy, University of the Basque Country (UPV), Campus of Vitoria, is led by Prof. José Luis Pedraz and consists of large laboratories for: cell culture, chromatography equipment, sample preparation and characterization and one specific for scale preparation of pharmaceutical formulations. This Unit has the capacity to design and evaluate dosage forms both classical and new dosage forms of biotech drugs, DNA, RNA and vaccines using different methodologies based on micro and nano-medicine. The latter methodology based on the microencapsulation of cells, peptides, proteins, and in general of biotech products, as well as the development and design of non-viral vectors for gene therapy, is one of the biggest singularities of this unit. It counts with the most advanced equipment for micro and nano encapsulation.
The aim of the Unit is to determine experimentally all the variables needed to develop an optimal formulation and work instructions for preparing final pharmaceutical products.
The pharmaceutical technology applied to drug development involves the selection of materials and procedures that can be adapted to different processes that lead to specific pharmaceutical forms. To do that, the Unit counts with the most advanced equipment to cover the development for all the steps of the process.
One of the singularities of this Units is that is GLP certified by the Spanish Medicament Agency
Services
FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE
U10. Services & Rates
Other projects
| Ref |
Title |
Funding Organism |
Unit Role |
| RTC-2016-4770-1 |
DEVELOPMENT OF A NEW BIOADHESIVE FOR PTERIGIUM SURGERY. BIOTAPE |
MINISTERIO DE ECONOMIA, INDUSTRIA Y COMPETITIVIDAD. |
Participant |
| RTC-2016-5451-1 |
DEVELOPMENT OF BIOIMPRESSION SYSTEMS AND BIOTINES FOR THREE-DIMENSIONAL CARTILAGE AND BONE REGENERATION |
MINISTERIO DE ECONOMIA, INDUSTRIA Y COMPETITIVIDAD. |
Participant |
| RTC-2015-3303-1 |
Lipid solid nanoparticles for subcutaneous administration of antitumor marine compounds - UNDERLIPIDS |
MINISTERIO DE ECONOMIA Y COMPETITIVIDAD |
|
Publications
2016
- Grijalvo S., Puras G., Zarate J., Pons R., Pedraz J.L., Eritja R. et al. Nioplexes encapsulated in supramolecular hybrid biohydrogels as versatile delivery platforms for nucleic acids. RSC Advances. 2016;6(46):39688-39699.
- Moreno-Sastre M., Pastor M., Esquisabel A., Sans E., Vinas M., Fleischer A. et al. Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis. International Journal of Pharmaceutics. 2016;498(1-2):263-273.
- Moreno-Sastre M., Pastor M., Esquisabel A., Sans E., Vinas M., Bachiller D. et al. Stability study of sodium colistimethate-loaded lipid nanoparticles. Journal of Microencapsulation. 2016;33(7):636-645.
- Garcia-Orue I., Gainza G., Gutierrez F.B., Aguirre J.J., Evora C., Pedraz J.L. et al. Novel nanofibrous dressings containing rhEGF and Aloe vera for wound healing applications. International Journal of Pharmaceutics. 2016;:-.
- Ojeda E., Puras G., Agirre M., Zarate J., Grijalvo S., Eritja R. et al. The role of helper lipids in the intracellular disposition and transfection efficiency of niosome formulations for gene delivery to retinal pigment epithelial cells. International Journal of Pharmaceutics. 2016;503(1-2):115-126.
- Ojeda E., Puras G., Agirre M., Zarate J., Grijalvo S., Eritja R. et al. The influence of the polar head-group of synthetic cationic lipids on the transfection efficiency mediated by niosomes in rat retina and brain. Biomaterials. 2016;77:267-279.
News U10
27 Jul
Researchers of NANBIOSIS U10 Drug Formulation unit of CIBER-BBN and UPV/EHU and NANBIOSIS U14 Cell Therapy unit and U24 Medical imaging unit at CCMIJU have participated in a research that proposes the use of encapsulated cardiosphere-derived cells (CDC), obtained from heart tissue, as regenerative cell therapy. “The encapsulation of the cells has been carried out [...]
07 Jul
Ibane Abasolo, the Scientific Coordinator of NANBIOSIS U20 of the CIBER-BBN at the Vall d’Hebron Research Institute (VHIR), has been appointed new Scientific Director, replacing Simó Schwartz, who has recently assumed the Directorate of the Blood and Tissue Bank of Catalonia. With her, there are 11 women who are Scientific Directors of NANBIOSIS units (46%), [...]
04 Mar
A new study with participation of NANBIOSIS Unit 10 Drug Formulation unit of CIBER-BBN and UPV/EHU, has succeeded in preventing and reversing pulmonary fibrosis in experimental models with PLGA / PEI nanoparticles loaded with the GSE4 peptide. These results are the first step to study its possible antifibrotic effect in patients with idiopathic pulmonary fibrosis [...]
26 Jan
The NanoBioCel Research group, led by Jose Luis Pedraz, from CIBER-BBN and UPV/EHU, group that coordinates the Unit U10 Drug Formulation of NANBIOSIS -ICTS, together with the Provincial Council of Álava and the Center for Technological Research and Development TECNALIA, have launched last Thursday, January 21, the new Center for Research in Advanced Pharmaceutical Development, [...]
28 Dec
Researchers of CIBER-BBN Units of NANBIOSIS: U29 Oligonucleotide Synthesis Platform (OSP) at IQAC_CSIC, led by Prof. Ramón Eritja and U10 Drug Formulation, at UPV-EHU, led by Prof José Luis Pedraz, are coauthors of an article published by International Journal of Pharmaceutics. Gene therapy strategies based on non-viral vectors are currently considered as a promising therapeutic option [...]
21 Nov
The NanoBioCell group, led by Prof. Jose Luis Pedraz, participates in the European project Moore4medical. A project to accelerate innovation in emergencing medical devices with open tecnhology platforms. The NanoBiocel group, will focus on the lyophilization process of biopharmaceuticals and their use in microfluidic devices The NanoBiocel research group of the University of the Basque [...]
19 Nov
The Bioaraba Health Research Institute has awarded Ainhoa González Pujana, a researcher at NanoBioCell and the Nanbiosis Platform through the U10 Drug Formulation (from CIBER-BBN and UPV-EHU), the award for the best doctoral thesis 2019 at the XXI Bioaraba Research and Innovation Conference, held last November 5 in Vitoria-Gasteiz. Along with the recognition, the award [...]
13 Nov
Researchers from the CIBER-BBN and NANBIOSIS are participating in a new project that aims to achieve the most effective, specific and economical pharmacological nanotherapy that allows delaying the death of retinal cells and subsequent loss of vision in hereditary retinal dystrophy. retinitis pigmentosa, regardless of the genetic defect causing the disease. In this project, coordinated [...]
11 Nov
The CIBER-BBN researcher at the University of the Basque Country (UPV-EHU), Laura Saenz del Burgo, received, within the framework of the XXI Bioaraba Research and Innovation Conference, the award for the “Best Emerging Researcher 2020”. The researcher of the NanoBioCel group of the UPV / EHU, who belongs to the CIBER BBN and the U10 [...]
10 Nov
TRIANKLE is an EU Project to develop regenerative therapies for ankel injuries in which participate NanoBioCell Group and NANBIOSIS U10 Drug Formulation unit (from CIBER-BBN and UPV/EHU), led by José Luis Pedraz. The main objective is to reduce the time of recovery down to 50% andincrease the functionality ratios up to 10-15%. Research consortium [...]
